Wang Liangshan, Wang Hong, Hou Xiaotong
Center for Cardiac Intensive Care, Capital Medical University Affiliated Anzhen Hospital, Beijing, People's Republic of China.
Center for Cardiac Intensive Care, Capital Medical University Affiliated Anzhen Hospital, Beijing, People's Republic of China.
J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2087-2093. doi: 10.1053/j.jvca.2018.03.016. Epub 2018 Mar 12.
To investigate the clinical outcomes of adult patients receiving extracorporeal membrane oxygenation (ECMO) for postcardiotomy cardiogenic shock (PCS).
Meta-analysis of 20 observational studies.
Hospitals that perform cardiac surgery.
The study included 2,877 PCS patients undergoing ECMO from 20 observational studies.
ECMO use.
Twenty observational studies were selected for final analysis. The pooled survival rate to hospital discharge was 34.0% (30.0%-38.0%) in PCS patients receiving ECMO. The pooled 1-year survival rate was 24.0% (19.05%-30.0%). The pooled midterm survival rate was 18.0% (11.0%-27.0%). The pooled rate of leg ischemia was 14.0% (10.0%-20.0%). The pooled rate of redo surgery was 50.0% (32.0%-68.0%). The pooled rate of renal failure was 57.0% (47.0%-66.0%). The pooled rate of neurologic complications was 16.0% (13.0%-20.0%). The pooled rate of infection was 31.0% (22.0%-41.0%). Most of the included studies commonly revealed that age >65 years, pre-ECMO or post-ECMO blood lactate, renal insufficiency, a longer duration of ECMO, and neurologic complications were risk factors of in-hospital mortality in PCS patients undergoing ECMO.
The short-term and midterm survival rates of PCS patients treated with ECMO were disappointingly low, and post-ECMO complication rates were relatively high.
探讨接受体外膜肺氧合(ECMO)治疗的心内直视术后心源性休克(PCS)成年患者的临床结局。
对20项观察性研究进行荟萃分析。
开展心脏手术的医院。
该研究纳入了来自20项观察性研究的2877例接受ECMO治疗的PCS患者。
使用ECMO。
选取20项观察性研究进行最终分析。接受ECMO治疗的PCS患者出院时的合并生存率为34.0%(30.0%-38.0%)。1年合并生存率为24.0%(19.05%-30.0%)。中期合并生存率为18.0%(11.0%-27.0%)。下肢缺血的合并发生率为14.0%(10.0%-20.0%)。再次手术的合并发生率为50.0%(32.0%-68.0%)。肾衰竭的合并发生率为57.0%(47.0%-66.0%)。神经系统并发症的合并发生率为16.0%(13.0%-20.0%)。感染的合并发生率为31.0%(22.0%-41.0%)。大多数纳入研究普遍显示,年龄>65岁、ECMO治疗前或治疗后血乳酸水平、肾功能不全、ECMO治疗持续时间较长以及神经系统并发症是接受ECMO治疗的PCS患者院内死亡的危险因素。
接受ECMO治疗的PCS患者的短期和中期生存率低得令人失望,且ECMO治疗后的并发症发生率相对较高。